Mechanisms coupling DEK to oncogenesis
Mechanisms coupling DEK to oncogenesis
批准号:
10091408
负责人:
Lisa M. Privette Vinnedge
金额:
$36.37万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-02-08 至 2023-01-31
关键词:
3-DimensionalAnimal ModelBlood VesselsBreast Cancer ModelBreast Cancer PatientBreast Cancer cell lineCancer BiologyCell Culture TechniquesCellsClinical Oncology Supplement (K12)CollaborationsCoupledCouplingCuesCytotoxic T-LymphocytesDEK geneDataDevelopmentDiseaseDisease ProgressionDoxycyclineERBB2 geneEnvironmentEpithelialEpithelial Cell ProliferationEpithelial CellsFutureGene ExpressionGenesGlandGoalsGrowthHistologicHormone ReceptorHormonesHumanHyperplasiaImmuneImmune systemImmunotherapyIn VitroInfectionInflammatoryKnockout MiceLigandsMaintenanceMalignant NeoplasmsMammary NeoplasmsMammary glandMediatingMediator of activation proteinModelingMolecularMusMyeloid CellsNeoplasm MetastasisNormal CellOncogenesOncogenicOrganoidsParacrine CommunicationPathway interactionsPatientsPhenotypePrognosisProteinsRoleSamplingSignal TransductionSolid NeoplasmSurvival RateTestingTherapeuticTherapeutic EffectTissue MicroarrayTissue SampleTissuesTumor-DerivedTumor-associated macrophagesTumor-infiltrating immune cellsUp-RegulationWNT Signaling PathwayWnt proteinsWorkXenograft procedureanti-tumor immune responseautocrinebreast tumorigenesiscancer cellcarcinogenesiscell stromachemical geneticschemotherapychromatin remodelingdifferential expressionfightingimprovedin vivolongitudinal analysismacrophagemalignant breast neoplasmmammary epitheliummigrationmolecular arraymolecular markermouse modelneoplasticneoplastic cellnoveloverexpressionparacrinepreventprogramsreceptorrecruitsmall hairpin RNAsmall molecule inhibitortargeted treatmentthree dimensional cell culturetranscriptome sequencingtreatment responsetriple-negative invasive breast carcinomatumortumor growthtumor initiationtumor progressiontumor-immune system interactionstumorigenesistumorigenic
中文摘要
点击翻译按钮获取中文摘要
英文摘要
1 Project Abstract: Although the number of people developing breast cancer (BC) each year has remained the
2 same, 5-year survival rates for late stage disease are still an abysmal 17-26%. However, one positive indicator
3 of survival is how well the patient’s immune system is able to recognize the tumor and attack it, using immune
4 cells like tumor-associated macrophages (TAMs). Basal-like, triple negative BC (TNBC) is a uniquely deadly
5 type of BC and accounts for about 20% of BC cases. TNBC does not grow because of hormone and growth
6 factors, but instead frequently activates other pro-growth signals like the expression of secreted WNT proteins
7 that act as messengers to nearby cells. In addition, TNBC is more likely to manipulate the immune system into
8 a tumor-promoting mechanism instead of a tumor-fighting one. This is accomplished by inducing TAMs to
9 program into a tumor-promoting M2 state, which helps create an environment for tumors to thrive by promoting
10 blood vessel growth, instead of a tumor-fighting M1 state. We have identified the DEK protein as a key driver of
11 BC growth and disease progression. DEK is highly expressed – meaning too much protein is made compared
12 to normal cells - in about 60% of all breast cancers, especially TNBC. DEK is over-expressed in all types of
13 cancer studied so far, meaning that understanding how DEK functions to promote cancer growth and disease
14 progression could have a far-reaching impact in understanding cancer biology. We have previously used cultured
15 cells to discover that DEK promotes the proliferation of cancer cells by increasing the expression of several WNT
16 genes that then get secreted to act on neighboring cells, but have not yet investigated this in animal models.
17 Interestingly, our preliminary data suggest that the WNT proteins produced by DEK-expressing cancer cells may
18 signal to TAMs to enter an M2-like state to further promote tumor growth. We hypothesize that DEK over-
19 expression in BC promotes tumor formation via elevated WNT expression, which acts both on neighboring
20 epithelial cells and on macrophages. We will use three-dimensional cell culture of human cells, patient samples,
21 and new mouse models of BC to test this hypothesis. In Aim 1, we will use a new DEK over-expression model
22 in the mammary epithelium of mice to Determine when and how DEK promotes tumor growth. We will also
23 determine the necessity for continued DEK expression to maintain tumor growth, which will inform the feasibility
24 of creating DEK-targeting therapies in the future. Aim 2 will investigate how important WNT proteins are for the
25 ability of DEK to promote tumor growth and progression. Finally, Aim 3 will examine how DEK and WNT proteins
26 work together to induce TAMs to enter the tumor-promoting M2 state. This work will be the first to both investigate
27 the consequences of DEK over-expression in an animal model and the first to examine the ability of WNT proteins
28 to signal to the immune system during cancer development and progression. Understanding how DEK promotes
29 tumor growth, including downstream effects on TAMs, will better inform therapeutic decisions that maximize
30 the collaboration between chemotherapy and the anti-‐tumor immune response.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms coupling DEK to oncogenesis
-
批准号:10765949
-
项目类别:
-
资助金额:$35.98万
-
财政年份:2018
-
负责人:Lisa M. Privette Vinnedge
-
依托单位:
Mechanisms coupling DEK to oncogenesis
-
批准号:10331305
-
项目类别:
-
资助金额:$36.37万
-
财政年份:2018
-
负责人:Lisa M. Privette Vinnedge
-
依托单位:
The role of DEK in breast cancer development and therapy
-
批准号:7675800
-
项目类别:
-
资助金额:$4.72万
-
财政年份:2009
-
负责人:Lisa M. Privette Vinnedge
-
依托单位:
The role of DEK in breast cancer development and therapy
-
批准号:7928091
-
项目类别:
-
资助金额:$5.05万
-
财政年份:2009
-
负责人:Lisa M. Privette Vinnedge
-
依托单位:
海外基金